comparemela.com

Latest Breaking News On - Icon public - Page 1 : comparemela.com

ICON Public Limited (NASDAQ:ICLR) Receives $321 64 Consensus PT from Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR – Get Free Report) have been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated their coverage on the […]

ICON Public Limited (NASDAQ:ICLR) Receives Consensus Rating of Buy from Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR – Get Free Report) have earned a consensus rating of “Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in […]

ICON Public Limited (NASDAQ:ICLR) Given Average Recommendation of Buy by Analysts

ICON Public Limited (NASDAQ:ICLR – Get Free Report) has been given an average recommendation of “Buy” by the eight brokerages that are currently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have updated their coverage on the stock […]

TD Cowen Boosts ICON Public (NASDAQ:ICLR) Price Target to $349 00

ICON Public (NASDAQ:ICLR – Free Report) had its price target raised by TD Cowen from $343.00 to $349.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a buy rating on the medical research company’s stock. Several other analysts have also recently issued reports on the company. Truist Financial […]

Evercore ISI Lowers ICON Public (NASDAQ:ICLR) Price Target to $330 00

ICON Public (NASDAQ:ICLR – Get Free Report) had its price target lowered by analysts at Evercore ISI from $350.00 to $330.00 in a report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s price target points to a potential upside of 7.04% from the […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.